Brokerage firm Baird Downgrades its rating on Stryker Corporation(NYSE:SYK). The shares have been rated Neutral. Previously, the analysts had a Outperform rating on the shares. The rating by Baird was issued on Apr 13, 2016.
In a different note, Nomura said it Initiates Coverage on Stryker Corporation, according to a research note issued on Mar 17, 2016. The shares have been rated ‘Neutral’ by the firm. On Feb 1, 2016, Deutsche Bank said it Maintains its rating on Stryker Corporation. In the research note, the firm Raises the price-target to $107.00 per share. The shares have been rated ‘Buy’ by the firm. On Jan 27, 2016, Brean Capital said it Upgrades its rating on Stryker Corporation. The shares have been rated ‘Buy’ by the firm.
Stryker Corporation (SYK) shares turned negative on Fridays trading session with the shares closing down -0.3 points or -0.27% at a volume of 15,88,442. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $110.09. The peak price level was also seen at $110.09 while the days lowest was $108.94. Finally the shares closed at $109.8. The 52-week high of the shares is $110.41 while the 52-week low is $86.68. According to the latest information available, the market cap of the company is $40,953 M.
Stryker Corporation(SYK) last announced its earnings results on Jan 26, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $2.71B. Analysts had an estimated revenue of $2.71B. Earnings per share were $1.56. Analysts had estimated an EPS of $1.55.
Several Insider Transactions has been reported to the SEC. On Apr 11, 2016, Ronda E Stryker (director) sold 12,000 shares at $108.46 per share price.Also, On Apr 5, 2016, Katherine Ann Owen (V.P., Strategy & Investor Rel.) sold 10,914 shares at $109.29 per share price.On Mar 15, 2016, Kevin Lobo (Chairman and CEO) sold 25,952 shares at $105.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Stryker Corporation is a medical technology company. The Company offers a range of products and services in Orthopaedics Medical and Surgical and Neurotechnology and Spine which help improve patient and hospital outcomes.